Loading...
XASX
PER
Market cap35mUSD
Jan 29, Last price  
0.06AUD
Name

Antisense Therapeutics Ltd

Chart & Performance

D1W1MN
XASX:PER chart
P/E
—
P/S
31.96
EPS
—
Div Yield, %
—
Shrs. gr., 5y
26.65%
Rev. gr., 5y
-55.61%
Revenues
2m
-11.14%
000762,3686,399,0000000003,863,9881,000,00069,1150586,788668,433577,7641,777,9041,579,849
Net income
-11m
L+95.06%
-4,609,624-6,265,839-5,462,401-4,835,963-2,136,886-2,649,727-3,424,875-1,813,550-1,801,278-2,454,842-3,013,272706,918-2,514,443-2,754,799-2,331,015-2,944,499-5,890,210-8,067,192-5,834,080-11,379,828
CFO
-8m
L+4.44%
-2,209,608-5,585,305-3,958,499-2,679,528-3,401,498-3,283,821-1,336,627-1,867,239-2,405,200-2,833,186-3,107,8861,268,875-2,025,026-2,914,222-2,301,793-2,928,436-3,945,358-5,834,156-7,805,166-8,151,329

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
URL
https://www.antisense.com.au/
IPO date
Dec 20, 2001
Employees
8
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT